Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2003

Open Access 01-12-2003 | Research article

vCJD risk in the Republic of Ireland

Authors: Michael S Harney, Azra C Ghani, CA Donnelly, Rory McConn Walsh, Michael Walsh, Rachel Howley, Francesca Brett, Michael Farrell

Published in: BMC Infectious Diseases | Issue 1/2003

Login to get access

Abstract

Background

The Republic of Ireland has the second highest incidence of BSE worldwide. Only a single case of vCJD has been identified to date.

Methods

We estimate the total future number of clinical cases of vCJD using an established mathematical model, and based on infectivity of bovine tissue calculated from UK data and on the relative exposure to BSE contaminated meat.

Results

We estimate 1 future clinical case (95% CI 0 – 15) of vCJD in the Republic of Ireland. Irish exposure is from BSE infected indigenous beef products and from imported UK beef products. Additionally, 2.5% of the Irish population was exposed to UK beef through residing in the UK during the 'at-risk' period. The relative proportion of risk attributable to each of these three exposures individually is 2:2:1 respectively.

Conclusions

The low numbers of future vCJD cases estimated in this study is reassuring for the Irish population and for other countries with a similar level of BSE exposure.
Appendix
Available only for authorised users
Literature
1.
Will RG, Ironside JW, Zeidler M, Cousens SN, Esteiboro K, Smith PG: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996, 347: 921-25. 10.1016/S0140-6736(96)91412-9.CrossRefPubMed
2.
Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Bostock CJ: Transmissions to mice indicate that 'new-variant' CJD is caused by the BSE agent. Nature. 1997, 389: 498-501. 10.1038/39057.CrossRefPubMed
3.
Collinge J, Sidle K, Meads J, Ironside J, Hill AF: Molecular analysis of prion strain variation and the aetiology of 'new-variant' CJD. Nature. 1996, 383: 685-90. 10.1038/383685a0.CrossRefPubMed
4.
Hill AF, Desbruslais M, Joiner S, Sidle K, Gowland I, Lantos P: The same prion strain causes vCJD and BSE. Nature. 1997, 389: 448-50. 10.1038/38925.CrossRefPubMed
5.
Anderson RM, Donnelly CA, Ferguson NM, Woolhouse ME, Watt CJ, Wells GA: Transmission dynamics and epidemiology of BSE in British cattle. Nature. 1996, 382: 779-788. 10.1038/382779a0.CrossRefPubMed
6.
Ferguson NM, Donnelly CA, Woolhouse M, Anderson RM: The epidemiology of BSE in cattle herds in Great Britain. II Model construction and analysis of transmission dynamics. Phil Trans R Soc Lond B. 1997, 352: 803-838. 10.1098/rstb.1997.0063.CrossRef
7.
Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM: Epidemiological determinants of the pattern and magnitude of the vCJD epidemic in Great Britain. Proc R Soc Lond B. 1998, 265: 2443-2452. 10.1098/rspb.1998.0596.CrossRef
8.
Ghani AC, Ferguson NM, Donnelly CA, Anderson RM: Predicted vCJD mortality in Great Britain. Nature. 2000, 406: 583-4. 10.1038/35020688.CrossRefPubMed
9.
Ghani AC, Ferguson NM, Donnelly CA, Anderson RM: Factors determining the pattern of the vCJD epidemic in Great Britain. Proc R Soc Lond B. 2003, 270: 689-698. 10.1098/rspb.2002.2313.CrossRef
10.
Ghani AC, Donnelly CA, Ferguson NM, Anderson RM: Updated projections of future vCJD deaths in the UK. BMC Infect Dis. 2003, 3: 4-10.1186/1471-2334-3-4.CrossRefPubMedPubMedCentral
11.
12.
Molloy S, O'Laoide R, Brett F, Farrell M: The "Pulvinar" sign in variant Creutzfeldt-Jakob disease.AJR. Am J Roentgenol. 2000, 175: 555-6.CrossRef
13.
14.
15.
Ferguson NM, Ghani AC, Donnelly CA, Denny GO, Anderson RM: BSE in Northern Ireland: epidemiological patterns past, present and future. Proc R Soc Lond B. 1998, 265: 545-554. 10.1098/rspb.1998.0329.CrossRef
16.
Donnelly CA, Ferguson NM, Ghani AC, Anderson RM: Implications of BSE infection screening data for the scale of the British BSE epidemic and current European infection levels. Proc R Soc Lond B. 2002, 269: 2179-90. 10.1098/rspb.2002.2156.CrossRef
17.
Beef imports on the Irish market: An Bord Bia Report. Dublin. 2001
18.
Donor & General Public Surveys for Irish Blood Transfusion Service: Drury Research. Dublin. 2001
19.
The National CJD Surveillance Unit: Creutzfeldt-Jakob disease surveillance in the UK. Western General Hospital, Edinburgh. 2002
20.
J Collinge, MS Palmer, AJ Dryden: Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet. 1991, 337: 1441-1442. 10.1016/0140-6736(91)93128-V.CrossRef
21.
F Owen, M Poulter, J Collinge, TJ Crow: Codon 129 changes in the prion protein gene in Caucasians. American Journal of Human Genetics. 1990, 46: 1215-1216.
22.
Hilton DA, Ghani AC, Conyers L, Edwards P, McArlde L, Ironside JW: Accumulation of prion protein in tonsil and appendix: review of tissue samples. BMJ. 2002, 325: 633-34. 10.1136/bmj.325.7365.633.CrossRefPubMedPubMedCentral
23.
WH Press, SA Teukolsky, WT Vetterling, BP Flannery: Numerical Recipes in C - The Art of Scientific Computing. 1992, Cambridge: CUP, 2
24.
Cervenakova L, Goldfarb LG, Garruto R, Lee HS, Gajdusek DC, Brown P: Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA. 1998, 95 (22): 13239-41. 10.1073/pnas.95.22.13239.CrossRefPubMedPubMedCentral
25.
Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Houston F: Transmission of prion diseases by blood transfusion. J Gen Virol. 2002, 83: 2897-905.CrossRefPubMed
26.
Glatzel M, Rogivue C, Ghani AC, Streffer JR, Amsler L, Aguzzi A: Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet. 2002, 360: 139-41. 10.1016/S0140-6736(02)09384-4.CrossRefPubMed
27.
Asante AE, Linehan JM, Desbruslais M, Joiner S, Gowland I, Collinge J: BSE prions propogate as either vCJD-like or sCJD-like prion strains in transgenic mice expressing human prion protein. EMBO. 2002, 21: 6358-6366. 10.1093/emboj/cdf653.CrossRef
Metadata
Title
vCJD risk in the Republic of Ireland
Authors
Michael S Harney
Azra C Ghani
CA Donnelly
Rory McConn Walsh
Michael Walsh
Rachel Howley
Francesca Brett
Michael Farrell
Publication date
01-12-2003
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2003
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-3-28

Other articles of this Issue 1/2003

BMC Infectious Diseases 1/2003 Go to the issue

Case report

Chlamydia trachomatisinfection in early neonatal period

Research article

Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein – conjugated pneumococcal vaccine in Filipino infants

Research article

RIDOM: Comprehensive and public sequence database for identification of Mycobacteriumspecies

Research article

Risk factors for high anti-HHV-8 antibody titers (≥1:51,200) in black, HIV-1 negative South African cancer patients: a case control study

Research article

Updated projections of future vCJD deaths in the UK

Research article

Prevention of poxvirus infection by tetrapyrroles
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits